Printer-friendly version |
The Gilead Access Program is designed to expand sustainable access to the once-daily anti-HIV medications Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Viread® (tenofovir disoproxil fumarate) in 97 developing countries.
The Program is one in a series of donations programs based on methods we helped develop. MCART provided all systems, data design, programming, front end work, and much conceptual planning.